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CHAPTER I 
 
LIGAND-BASED COMPUTER AIDED DRUG DESIGN 
 
Introduction 
On October 5, 1981, Fortune magazine published a cover article entitled the “Next 
Industrial Revolution: Designing Drugs by Computer at Merck” [1]. Some have credited this as 
being the start of intense interest in the potential for Computer Aided Drug Design (CADD). 
While progress was being made in CADD, the potential for high-throughput screening (HTS) had 
begun to take precedence as a means for finding novel therapeutics. This brute force approach 
relies on automation to screen high numbers of molecules in search of those which elicit the 
desired biological response. This method requires little compound design or prior knowledge 
and the efficiency of technologies required to screen large libraries continues to increase.  
However, while traditional HTS is often successful in the discovery of multiple lead compounds, 
the hit rate for this method is extremely low. This low hit rate has limited the usage of HTS to 
research programs capable of screening very large compound libraries. In the past decade, 
CADD has reemerged as a way to significantly decrease the number of compounds necessary to 
screen while retaining the same level of lead compound discovery. CADD techniques allow 
compounds predicted as inactive to be skipped and those predicted as active to be prioritized. 
This reduces the cost and workload of a full HTS screen without sacrificing lead discovery. For 
example, researchers at Pharmacia (now part of Pfizer) used CADD tools to screen for inhibitors 
of tyrosine phosphatase-1B, an enzyme implicated in diabetes. Their CADD-based virtual screen 
yielded 365 compounds, 127 of which showed effective inhibition, a hit rate of nearly 35%. 
Simultaneously, this group performed a traditional HTS against the same target. Of the 400,000 
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compounds tested, 81 showed inhibition, producing a hit rate of only .021%. This comparative 
case effectively displays the power of CADD for reducing the number of compounds necessary 
to test for hit discover [2]. CADD has already been used in the discovery of compounds which 
have passed clinical trials and become novel therapeutics in use for the treatment of a variety of 
diseases. Some of the earliest examples of approved drugs that owe their discovery in large part 
to the tools of CADD include the carbonic anhydrase inhibitor dorzolamide, approved in 1995 
[3], the ACE inhibitor captopril, approved in 1981 as an antihypertensive drug [4], three 
therapeutics for the treatment of HIV: saquinavir (approved in 1995), ritonavir and indinavir 
(both approved in 1996) [1] and tirofiban, a fibrinogen antagonist approved in 1998 [5].  
One example that helps validate the use of CADD in lead compound discovery is the 
search for novel TGF-beta-1 receptor kinase inhibitors in 2003. One group at Eli Lilly used a 
traditional high throughput screening to identify a lead compound that was subsequently 
optimized [6], while a group at Biogen Idec used a CADD approach involving virtual HTS based 
on the structural interactions between a weak inhibitor and TGF-beta-1 receptor kinase [7]. 
Upon the virtual screening of compounds, the group at Biogen Idec identified 87 hits, the best 
hit being identical in structure to the lead compound discovered through the traditional HTS 
approach at Eli Lilly [8]. In this situation CADD, a method involving reduced cost and workload, 
was capable of producing the same lead as a full-scale HTS. 
 
Position of CADD in the drug discovery pipeline 
CADD is capable of increasing the hit rate of novel drug compounds as it employs a 
much more targeted search than traditional HTS and combinatorial chemistry. It not only aims 
to explain the molecular basis of therapeutic activity, but also to predict possible derivatives 
that would improve activity. One of the most common uses in CADD is the screening of virtual 
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compound libraries, also known as virtual high-throughput screening (vHTS). This allows 
experimentalists to focus resources on testing compounds likely to have an activity of interest. 
Ripphausen et al. note that the first mention of vHTS was in 1997 [9] and chart an increasing 
rate of publication for the application of vHTS between 1997 and 2010. They also found that the 
largest fraction of hits has been obtained for GPCR’s, followed by kinases [10].  
vHTS comes in many forms including chemical similarity searches by fingerprints or 
topology, selecting compounds by predicted biological activity through Quantitative Structure-
Activity Relationship (QSAR) models or pharmacophore mapping, and structure-based docking 
[11]. These methods allow the ranking of “hits” from the virtual compound library for 
acquisition. The ranking can reflect a property of interest such as percent similarity to a query 
compound, predicted biological activity, or in the case of docking, the lowest energy scoring 
poses for each ligand bound to the target of interest. Often initial hits are rescored and ranked 
using higher level computational techniques that are too time-consuming to be applied to full 
scale vHTS. It is important to note that vHTS does not aim to identify a drug-compound that is 
ready for clinical testing, but rather to find leads with chemotypes that have not previously been 
associated with a target. This is not unlike a traditional HTS. Through iterative rounds of 
chemical synthesis and in vitro testing, a compound is developed into a “lead” with higher 
affinity and some understanding of is structure-activity-relation. This lead can then be tested for 
its DMPK/ADMET properties. Only after further iterative rounds of lead-to-drug optimization 
and in vivo testing does a compound reach a clinically appropriate potency and acceptable 
DMPK/ADMET properties [12]. For example, the literature survey performed by Ripphausen et 
al revealed that a majority of successful vHTS applications identified a small number of hits that 
are active in the micromolar range, and hits with low nanomolar potency are only rarely 
identified [10]. 
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Ligand-Based Computer-Aided Drug Design (LB-CADD) 
The ligand-based computer-aided drug discovery (LB-CADD) approach involves the 
analysis of ligands known to interact with a target of interest. These methods utilize a set of 
reference structures collected from compounds known to interact with the target of interest 
and analyze their 2D or 3D structures. The overall goal is to represent these compounds in such 
a way that the physicochemical properties most important for their desired interactions are 
retained while extraneous information not relevant to their interactions is discarded. LB-CADD is 
based on the Similar Property Principle, published by Johnson and Maggiora, which states that 
molecules that are structurally similar are likely to have similar properties [13]. It is considered 
an indirect approach to drug discovery in that it does not necessitate any prior knowledge of the 
target of interest. LB-CADD approaches are commonly applied when the 3D structure of the 
biological target is unknown. The two fundamental approaches of LB-CADD are a) selection of 
compounds based on chemical similarity to known actives using some similarity measure or b) 
the construction of a Quantitative Structure-Activity Relation (QSAR) model that predicts 
biological activity from chemical structure. The difference between the two approaches is that 
the latter weights features of the chemical structure according to their influence on the 
biological activity of interest, the former does not. The methods are applied for in silico 
screening for novel compounds possessing the biological activity of interest, hit-to-lead and 
lead-to drug optimization, and also for the optimization of DMPK/ADMET properties.  
 
Molecular Fingerprint and Similarity Searching 
Molecular fingerprint-based techniques attempt to represent molecules in such a way 
as to allow rapid structural comparison in an effort to identify structurally similar molecules or 
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to cluster collections based on structural similarity. These methods are less hypothesis-driven 
and less computationally expensive than pharmacophore mapping or QSAR. They rely entirely 
on chemical structure and do not take compound potency/activity into account, making the 
approach more qualitative in nature than other LB-CADD approaches [14]. Additionally, 
fingerprint-based methods do not attempt to focus only on parts of a molecule that are thought 
to be most important for activity but rather they consider all parts of the molecule equally. This 
is less prone to errors than hypothesis-driven methods but suffers from the influence of 
unnecessary features [14]. Despite this drawback, 2-dimensional fingerprints continue to be the 
representation of choice for similarity-based virtual screening [15]. Not only are these methods 
the computationally least expensive way to compare molecular structures [16], but their 
effectiveness has been demonstrated in many comparative studies [15]. 
Fingerprint Types 
Fingerprints are bit string representations of molecular structure and/or properties [17, 
18]. They encode various molecular features as pre-defined bit settings [14] i.e. representation 
as 1 or 0, where 1 means feature is present or 0 if not. This allows chemical identity to be 
unambiguously assigned by the presence or absence of specific features [16]. The features 
described in a molecular fingerprint can vary in number and complexity (from hundreds of bits 
for structural fragments to thousands for connectivity fingerprints, and millions for the complex 
pharmacophore-like fingerprints) [14], depending on the computational resources available and 
the intended application. Fingerprints which rely solely on interatomic connectivity – i.e. 
molecular constitution – are known as 2-dimensional fingerprints [16]. In the prototypic 2D 
keyed fingerprint design, each bit position is associated with the presence or absence of a 
specific substructure pattern – for example carbonyl group attached to sp3 carbon, hydroxyl 
group attached to sp3 carbon, etc. [19]. 
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Molecular structure itself comprises several levels of organization between the atoms 
within a molecule and therefore fingerprints too may differ in their levels of organization. For 
example, the simplest fingerprint may contain the information that a given compound contains 
six carbon atoms and six hydrogen atoms. However, up to 217 different isomers can contain this 
fingerprint. Adding connectivity increases the specificity of the fingerprints but does not 
necessarily provide discrimination between stereoisomers. These molecules are not identical 
despite have equal constitutions and 2D fingerprints are insufficient to distinguish their 
structures. Therefore, considerable effort is taken to ensure the efficient application of 
fingerprints without sacrificing important molecular characteristics. One extension to 
fingerprints is the use of hash codes. These are bit strings of fixed length that contain 
information about connectivity, stereocenters, isotope labeling, and further properties. This 
information is then compressed to avoid redundancies [20]. Unfortunately, it is not always 
obvious which of these characteristics are important in a given context and which are not [16].  
Commonly used bit strings include the ISIS (Integrated Scientific Information System) 
keys with 166 bits and the MDL (Molecular Design Limited) [21] MACCS (Molecular ACCess 
System) keys [22] with 960 bits. The ISIS keys are small topological substructure fragments while 
the MACCS keys consist of the ISIS keys plus algorithmically generated more abstract atom-pair 
descriptors. MDL keys are commonly used when optimizing diversity [23, 24]. For example, the 
PubChem database uses a fingerprint that is 881 bits long to rank substances against a query 
compound. This fingerprint is comprised of the number and type of elements, ring systems 
(saturated and unsaturated up to a size of 10), pair-wise atom combinations, sequences, and 
substructures [16]. 
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Similarity Measures 
Molecular fingerprints are commonly used in ligand-based drug design to search a large 
database of fingerprints against a query molecule. In order to be effective, the search algorithm 
must employ a means of scoring the similarity between the query fingerprint and those in the 
database. Pairwise comparison of bit string overlap serves as the criterion for similarity and is 
based on the calculation of similarity coefficients [25]. The most commonly used similarity 
coefficient is the Tanimoto coefficient and is defined by the equation: 
 
                       
   
          
 
 
where   is the number of bits set to 1 in fingerprint A,   is the number of bits set  to 1 in 
fingerprint B, and    is the number of common bits [14]. The Tanimoto coefficient, however, 
is not always the best similarity coefficient. For example, it typically yields low similarity values 
when the query fingerprint has just a few bits set to 1 [26].  
While the Tanimoto coefficient is the most popular score equation, there are several 
others that have been proposed and the use of different scoring coefficients has been explored. 
Willett, et al. compares the different coefficients in detail, considering the use of data fusion 
methods for combining the results of database searches that use the same query but different 
similarity coefficients. They were unable to identify a single combination of coefficients that 
yielded the greatest performance in all circumstances. However, they did find that different 
coefficients consistently performed better than others within a given molecular size. For 
example, the Russell-Rao coefficient appeared in many of the best combinations involving 
smaller active molecules and the Tanimoto coefficient tended to retrieve molecules from the 
center of the size distribution[15]. 
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Similarity Searches in LB-CADD 
Fingerprint methods may be employed to search databases for compounds similar in 
structure to a lead query, providing an extended collection of compounds that can be tested for 
improved properties over the lead. In many situations, 2D similarity searches of databases are 
performed using chemotype information from first generation hits, leading to modifications that 
can be evaluated computationally or ordered for in vitro testing [4]. Bologa et al used 2D 
fingerprint and 3D shape-similarity searches to identify novel agonists of the estradiol receptor 
family receptor GPR30. This work yielded a first-in-class selective agonist with a KI of 11 nM [27]. 
SecinH3, a lead compound targeting cytohesins involved in insulin signaling initially identified 
with classical HTS, was used as a query molecule in a 2D-fingerprint search that yielded 26 novel 
cytohesin inhibitors, all of which were more potent than SecinH3 [28]. 2D pharmacophoric 
fingerprints were also used to identify novel T-type calcium channel blockers. Of the 38 
molecules selected for testing, 16 showed more than 50% blockade of CaV3.2 mediated T-type 
current. These compounds proved to be an interesting collection of T-type calcium channel 
blockers. Some showed reversible inhibition while others resulted in irreversible inhibition and 
one of the compounds caused alterations in depolarization/repolarization kinetics [29]. 
In addition to the enrichment of lead compound population, fingerprints are also used 
to increase molecular diversity of test compounds. Fingerprints can be used to cluster large 
libraries of hits in order to allow the sampling of a wide range of compounds without the need 
to sample the entire library. In this case, fingerprints are used to optimize the sampling of 
diversity space. The Jarvis-Patrick method which calculates a list of nearest neighbors for each 
molecule has been shown to perform well for chemical clustering. Two structures cluster 
together if they are in each-others list of nearest neighbors and they have at least K of their J 
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nearest neighbors in common. The MDL keys also provide a way to eliminate compounds which 
are least likely to satisfy the drug-likeness criterion [23]. 
Fingerprint Extensions 
Current research is focused on improving fingerprint-based LB-CADD methods. As 
mentioned, one drawback with fingerprint-based methods is that all features of a query 
molecule are equally important for ranking candidate molecules, regardless of any effect of 
these features on the biological activity at a target. One group, Hessler et al. proposes a method 
that intends to combine the advantages of similarity and pharmacophore searching on the basis 
of 2D structural representations only. In their proposed method, a set of query molecules is 
converted into a topological model (MTree) based on chemically reasonable matching of 
corresponding functional groups. This creates a topological map of the most similar fragments 
from a set of structurally diverse but active molecules and conserved features are characterized 
by high similarity scores of the corresponding nodes in the MTree model [30]. Due to the low 
dependence on chemical substructures, they argue that the MTree model is especially useful for 
identification of alternative novel molecular scaffolds or chemotypes. Methods for forming 
multiple feature tree models and multiple feature tree scoring schemes are also presented. 
 
Pharmacophores – Superimposing Active Compounds 
In 1998, the IUPAC formally defined a pharmacophore as ‘the ensemble of steric and 
electronic features that is necessary to ensure the optimal supramolecular interactions with a 
specific biological target structure and to trigger (or to block) its biological response’ [31]. In 
terms of drug activity, a pharmacophore is the spatial arrangement of functional groups that a 
compound or drug must contain in order to evoke a desired biological response. Therefore, an 
effective pharmacophore will contain information about functional groups that interact with the 
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target, as well as information regarding the type of non-covalent interactions and interatomic 
distances between these functional groups/interactions. This arrangement can be derived either 
in a structure-based manner by mapping the sites of contact between a ligand and binding site, 
or using a ligand-based approach. To generate a ligand-based pharmacophore, multiple active 
compounds are overlaid in such a way that a maximum number of chemical features overlap 
geometrically [32]. This can involve rigid 2D or 3D structural representations or, in more precise 
applications, incorporate molecular flexibility to determine overlapping sites. This 
conformational flexibility can be incorporated by pre-computing the conformational space of 
each ligand and creating a general-purpose conformational model or conformations can be 
explored by changing molecule coordinates as needed by the alignment algorithm [32]. For 
example, one popular pharmacophore-generating software package, Catalyst, uses the Poling 
algorithm [33] to generate approximately 250 conformers that it uses in its pharmacophore 
generation algorithm [34]. In a study targeting HSP90α, Al-Sha’er et al used 83 known reference 
molecules to generate pharmacophore queries and identified  twenty-five diverse inhibitors 
including three with IC50 values below 10 nM [35]. 
Pharmacophore Overlaying 
Molecules are commonly aligned through either a point-based or property-based 
technique. The point-based technique is the most widely used method and involves superposing 
pairs of points (atoms or chemical features) by minimizing Euclidean distances. The alignment of 
pharmacophore features is the most commonly used method when screening libraries against a 
query pharmacophore as well as for generating a pharmacophore. Property-based alignment 
techniques, on the other hand, use molecular field descriptors to generate alignments. They 
define a grid around each ligand and calculate interaction energies at each point between the 
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ligand and specific probe molecules. Overlapping interaction energies are used to guide 
alignments [32].  
Pharmacophore feature extraction 
A pharmacophore feature map is carefully constructed so as to balance generalizability 
with specificity. A general definition might categorize all functional groups having similar 
physiochemical properties (i.e. similar hydrogen-bonding behavior, ionizability) into one group 
whereas specific feature definitions may include such things as specific atom types at specific 
locations. More general feature definitions allow the identification of novel scaffolds and 
increase the population of compounds that match the pharmacophore. However, some degree 
of restriction is necessary for a pharmacophore’s predictive power to avoid high numbers of 
false positives which would result in poor LB-vHTS performance. The level of feature definition 
generalizability is usually determined by the algorithm used to extract feature maps and through 
user-specified parameters. The most common features used to define pharmacophore maps are 
hydrogen bond acceptors and donors (covalently bound, partially positive hydrogen atoms 
interact with a partially negative atom), acidic and basic groups (groups of atoms that are likely 
to be protonated or deprotonated at physiological pH), aromatic rings, aliphatic hydrophobic 
moieties, and aromatic hydrophobic moieties [34]. These are commonly implemented as 
spheres with a certain tolerance radius for pharmacophore matching [32]. 
Pharmacophore Algorithms and Software Packages 
The most common software packages employed for ligand-based pharmacophore 
generation include Phase [36], MOE [37], Catalyst [38, 39], and LigandScout [40]. Catalyst 
contains multiple tools for constructing pharmacophores. One such tool, HipHop, generates 
pharmacophores based on active molecules. Catalyst HypoGen is another pharmacophore 
module of Catalyst that uses a full range of training set compounds including inactive and active 
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compounds. The pharmacophore generated reflects not only features common among active 
compounds but also features missing from inactive compounds. HypoGen first finds all common 
features amongst actives and then removes the features common amongst the inactives. 
Simulated annealing is then employed to optimize the results returning up to ten different 
models [41]. These software packages provide different strengths and weaknesses depending 
on different implementations of certain features. For example, Catalyst only permits a single 
bonding feature per heavy atom while LigandScout allows a hydrogen-bond donor or acceptor 
to be involved in more than one hydrogen-bonding interaction [32]. MOE, on the other hand, 
allows a more customizable approach to hydrogen-bonding features. Lipophilic areas are 
generally represented as spheres located on hydrophobic atom chains, branches, or groups in a 
similar manner across software packages but with slight nuances. While subtle, these 
differences have important consequences on prediction models. For example, software 
packages that do not attach a hydrophobic feature to an aromatic ring are unable to predict that 
an aromatic group may be positioned in a lipophilic binding pocket [32]. Different algorithms 
provide different levels of customizability for user defined features. Catalyst allows the 
specification of one or more chemical groups that satisfy a particular feature while Phase allows 
not only matching chemical groups but also a list of exclusions for a given feature. MOE offers a 
level of customization that allows the user to implement entirely novel pharmacophore schemes 
as well as modification of existing schemes. However, this requires additional levels of expertise 
to program[32]. DISCO is another commonly used pharmacophore tool that determines the 
spatial orientation of common points among all active compounds and incorporates flexibility by 
accepting conformational ensembles for each compound. The features identified with DISCO 
include hydrophobic centers, hydrogen-bonding, and positive and negative charges [41]. GASP 
(Genetic Algorithm Similarity Program) incorporates conformational flexibility while overlaying 
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the compounds. It attempts to optimize the conformation by fitting them to similarity 
constraints and weighing the conformations that fit these constraints more than conformations 
that do not [41]. For a comprehensive analysis of the differences between commercial 
pharmacophore software packages, please see the 2008 review by Wolber et al [32]. 
Pharmacophore Mapping Applications 
Ligand-based pharmacophore methods have been used for the discovery of novel 
compounds across a variety of targets, resulting in the discovery of compounds showing activity 
in the micromolar and nanomolar range as well as compounds that reflect proof of concept with 
in vivo disease models. Al-Sha’er et al used 83 known Hsp90-α inhibitors to generate a 
pharmacophore model which resulted in the identification of several compounds, including one 
with an IC50 of 25 nM [35]. Schuster, et al. used Catalyst to create a pharmacophore model that 
was used to screen for 17β-HSD3 inhibitors. Hydroxysteroid dehydrogenases (HSD3) catalyze the 
reduction of alcohols or carbonyls and are suggested therapeutic targets for control of estrogen 
and androgen-dependent diseases such as breast and prostate cancer, acne, and hair loss [42]. 
Fifteen top scoring hits were tested in vitro at 2 µM and the most potent compound was able to 
inhibit 17β-HSD3 by 67.1% at 2 µM [42]. Noha et al developed 5-point pharmacophore models 
using the HipHop algorithm of Catalyst based on a training set of compounds with IC50 < 100 nM 
against IKK-β as potential anti-inflammatory and chemosensitizing agents. The authors used 128 
active and 44 inactive compounds to develop a pharmacophore model [43]. Their model was 
further refined with exclusion volume spheres and shape constraints to improve the scoring of 
compounds in their virtual high-throughput screen against the National Cancer Institute 
molecular database. Ten compounds were selected and the most potent compound 
(NSC719177) showed inhibitory activity against IKK-β in a cell free in vitro assay with IC50 of 6.95 
µM. Additionally, this compound inhibited NF-kappaB activation induced by TNF-alpha in 
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HEK293 cells with an IC50 of 5.85 µM [43]. Chiang et al used the HypoGen module of Catalyst to 
generate pharmacophore models based on an indole series of 21 compounds that showed anti-
proliferative activity through the inhibition of tubulin polymerization/microtubule 
depolymerization as novel treatments for cancer [44]. 130,000 compounds were screened and 
four novel compounds were discovered with anti-proliferative activity. The most potent 
compound displayed anti-proliferative activity in human cancer KB cells with an IC50 of 187 nM. 
This compound also inhibited the proliferation of other cancer cell types including MCF-7, NCI-
H460, and SF-268 and demonstrated anti-cancer effects in a histoculture system. In vitro assays 
revealed that this compound inhibited tubulin polymerization with an IC50 of 4.4 µM [44]. 
Doddareddy et al generated a pharmacophore model containing 3 hydrophobic regions, one 
positive ionizable center, and 2 hydrogen bond acceptor groups for the identification of novel 
selective T-type calcium channel blockers. The most potent hit showed an IC50 of 100 nM [45, 
46]. T-type calcium channels are involved in rhythmical firing patterns in the CNS and present 
therapeutic targets for the treatment of epilepsy and neuropathetic pain [29]. Manetti et al 
screened the Asinex and Chembridge databases using a pharmacophore designed to bind the 
ATP binding site of Abl. The most potent compound tested in vitro showed an IC50 of 16 nM [47]. 
Lanier et al used 3D pharmacophores containing five feature points and an exclusion sphere 
generated in MOE to filter a set of generated structures for optimal side chain selection for 
gonadotropin releasing hormone receptor [48]. 13 molecules were tested and the most active 
molecule showed a KI of 50 nM. Antagonists of the H3 histamine receptor have been suggested 
as potential therapeutics for the treatment of obesity. Roche et al used known H3 antagonists to 
generate a 3D pharmacophore model with four features including a distal positive charge, an 
electron rich position, a central aromatic ring, and either a second basic amine or another 
aromatic[49]. This model was used in a de novo approach with the Skelgen software [50] to 
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generate novel compounds from fragment libraries that match the pharmacophoric restraints. 
Discovered compounds showed selectivity for H3 versus the other histamine receptors H1, H2, 
and H4. Their most potent compound showed inverse agonist activity with an EC50 of 200 pM in 
a GTPγS functional assay and a binding affinity KI towards H3 of 9.8 nM[49]. 
Chao et al used pharmacophore-based design to take advantage of the therapeutic 
benefits of Indole-3-carbinol (I3C) in the treatment of cancer. I3C is known to suppress 
proliferation and induce apoptosis of various cancer cells through the inhibition of Akt activation 
[51, 52]. I3C, however, has a poor metabolic profile and low potency, likely due to the fact that 
its therapeutic behavior comes from only four of its metabolites. By overlaying these low energy 
conformers of these four metabolites, Chao et al was able to identify similar N-N’ distances and 
overlapping indole rings [53]. This led them to design SR13650 which showed an IC50 of 80 nM. 
Tumor xenograft studies using MCF-7 cells revealed antitumor effects at 10 mg/kg for 30 days. 
Computational analysis was also applied to increase the bioavailability and three compounds 
showed 45-60% tumor growth inhibition in vivo compared to the 26% growth inhibition of 
SR13650. SR13668 was the most potent compound and also displayed antitumor effects in other 
xenograft models. In vitro, SR13668 was shown to inhibit Akt activation by blocking growth-
factor stimulated phosphorylation and showed favorable toxicological profiles [53]. This drug is 
currently in phase 0 trials for the treatment of cancer [54].  
Raveendra et al. used pharmacophore modeling in an effort to identify novel HIV-1 
integrase (IN, enzyme mediator of the integration of viral cDNA into the host genome) 
inhibitors. This model was created with the HipHop algorithm within Catalyst and was based on 
the Quinolone 3-carboxylic acid class of IN inhibitors that show IC50 values ranging from 43.5 to 
7.2 nM and EC50 against HIV-1 replication of 805 to 0.9 nM [55]. The final pharmacophore 
hypothesis consisted of four features including a negatively ionizable feature, hydrogen-bond 
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acceptor, and two hydrophobic aromatic features. 362,260 commercially available compounds 
were screened and 56 selected for in vitro evaluation. 11 of those tested inhibited the IN 
catalytic activity with an IC50 value < 100 µM. Five compounds had an IC50 less than 20 µM and 
the most potent compound inhibited both the 3’ processing (IC50 14 µM) as well as strand 
transfer activities (IC50 5 µM) of IN[56] . Mugnaini et al created a pharmacophore model and 
screened the ASINEX database for inhibitors of IN. One compound selected for in vitro testing 
had a novel scaffold and anti-integrase activity with IC50 of 164 µM. Further improvement of this 
compound yielded an analogue with IC50 of 12 µM [57]. 
Noeske, et al [58] used 2D-pharmacophore-based virtual screening to identify novel 
mGlu1 antagonists. Antagonism of this receptor has been studied in regards to therapeutic 
potential in neurodegenerative diseases, anxiety, pain, and schizophrenia [59, 60]. Six reference 
mGlu1 antagonists were used to construct 2D-pharmacophores with the CATS software package 
[61]. This software assigns all atoms in a compound as either a hydrogen-bond donor, hydrogen-
bond acceptor, positively charged, negatively charged, lipophilic, or non-interest atom type. 
Then, all compounds of a library are compared with the distances between these different atom 
types in the reference molecule and similarity scores are calculated to rank molecules that most 
closely fit this 2D-pharmacophore. Screening the Gold Collection of Asinex Ltd yielded six 
different hit lists (one for each reference molecule). The top hits were collected from all lists as 
well as hits that appeared in three or more different lists and 23 compounds were tested 
experimentally for mGlu1 antagonism. Their most potent compound yielded an IC50 of 360 nM 
and was further optimized to a compound with an IC50 of 123 nM. 
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Quantitative Structure Activity Relationship (QSAR) 
Quantitative structure-activity relationship (QSAR) models describe the mathematical 
relation between structural attributes and target response of a set of chemicals [62]. Classical 
QSAR is known as the Hansch-Fujita approach and involves the correlation of various electronic, 
hydrophobic, and steric features with biological activity. In the 1960s, Cowin Hansch and others 
began to establish QSAR models using various molecular descriptors to physical, chemical, and 
biological properties focused on providing computational estimates for the bioactivity of 
molecules [63]. In 1964, Free-Wilson developed a mathematical model relating the presence of 
various chemical substituents to biological activity (each type of chemical group was assigned an 
activity contribution) and the two methods were later combined to create the Hansch/Free-
Wilson method [64, 65]. The general workflow of a QSAR-based drug discovery project is to first 
collect a group of active and inactive ligands and then create a set of mathematical descriptors 
that describe the physicochemical and structural properties of those compounds. A model is 
then generated to identify the relationship between those descriptors and the ligands’ 
experimental activity maximizing the predictive power. Finally, that model is applied to a library 
of compounds which are defined with the same descriptors. In this way, experimental activities 
of these compounds can be predicted and ranked. Success of QSAR, therefore, depends not only 
on the quality of the initial set of active/inactive compounds, but also on the choice of 
descriptors and the ability to generate the appropriate mathematical relationship. One of the 
most important considerations regarding this method is the fact that all models generated will 
be dependent on the sampling space of the initial set of compounds with known activity and 
their chemical diversity. In other words, divergent scaffolds or functional groups not 
represented within this “training” set of compounds will not be represented in the final model 
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and any potential hits within the library to be screened that contain these groups will likely be 
missed. Therefore, it is most advantageous to cover a wide chemical space within the training 
set. For a comprehensive guide on performing a QSAR-based virtual screen, please see the 
review by Zhang [62]. 
Descriptor Types 
Molecular descriptors can be structural as well as physicochemical and, like molecular 
fingerprints, can be described on multiple levels of increasing complexity. Information described 
can include properties such as molecular weight, geometry, volume, surface areas, ring content, 
rotatable bonds, inter-atomic distances, bond distances, atom types, planar and non-planar 
systems, molecular walk counts, electronegativities, polarizabilities, symmetry, atom 
distribution, topological charge indices, functional group composition, aromaticity indices, 
solvation properties, and many others [24, 66-72]. These descriptors are generated through 
knowledge-based methods, molecular-mechanical, or quantum-mechanical tools [34] and are 
classified according to the dimensionality of the chemical representation from which they are 
computed [73]. One-dimensional descriptors encode properties such as molecular weight, 
refractivity, and solubility [73]. 2D descriptors are commonly computed from topological 
representations of molecules while 3D descriptors are obtained from the 3D structure of the 
molecule [73].  
Many two-dimension molecular descriptors are based on graph theoretic indices and 
represent different aspects of molecular structures. The physicochemical meaning of these 
indices, however, is unclear and incapable of representing some qualities which are inherently 
three-dimensional (stereochemistry). Three-dimensional molecular descriptors were developed 
to address some of these issues [74]. Radial distribution functions (RDFs) are the most popular 
3D descriptors. RDFs map the probability distribution to find an atom in a spherical volume of 
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radius r. In its simplest form, the RDF maps the interatomic distances within the entire molecule. 
Often it is combined with characteristic atom properties in order to fit the requirements of the 
information to be represented [66]. RDFs not only provide information regarding interatomic 
distances between atoms and properties, they reflect other information such as bond distances, 
ring types, and planar versus non-planar molecules. These functions allow estimation of 
molecular flexibility through the use of a “fuzziness” coefficient that extends the width of all 
peaks to allow for small changes in interatomic distances. The equation for a property weighted 
radial distribution function is shown, where   represents the scaling factor,    is the atomic 
weighting property for atom  ,    is the atomic weighting property for atom  ,   is the 
“fuzziness” coefficient,     is the distance between atoms   and  , and  is the number of atoms 
in the molecule: 
 ( )   ∑∑     
  (     )
 
 
    
   
 
 
 
CoMFA [72] is another very popular three-dimension QSAR techniques, established over 
twenty years ago as a standard technique for constructing three-dimensional models in the 
absence of direct structural data of the target. In this method, molecules are aligned based on 
their three-dimensional structures on a grid and the values of steric (VDW interactions) and 
electrostatic potential energies (Coulombic interactions) are calculated at each grid point. Then 
a multivariable linear regression or partial least squares model is used to predict activity from 
these features. Comparative Molecular Similarity Indices (CoMSIA) is an important extension to 
CoMFA. In CoMSIA, the molecular field includes hydrophobic and hydrogen-bonding terms in 
addition to the steric and coulombic contributions. Similarity indices are calculated instead of 
interaction energies by comparing each ligand with a common probe and Gaussian-type 
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functions are used to avoid extreme values [75]. One important limitation to these methods, 
however, is that their applicability is limited to static structures of similar scaffolds while 
neglecting the dynamical nature of the ligands [34]. COMFA and CoMSIA translate the 
pharmacophore hypothesis directly into a QSAR method.  
Hristozov, et al. analyzed the performance of different descriptors across a range of 
benchmarking datasets and found that the performance of a particular descriptor was often 
dependent on the activity class. It was found that topological autocorrelation usually offers the 
best dimensionality/performance ratio. The fusion of the ranked lists obtained with RDF codes 
and 2D descriptor improved results because RDF codes, while giving similar results, covered 
different parts of the activity spaces under investigation [76]. Increasing the size of training set 
beyond 100 compounds did not bring a significant improvement in all scenarios.  
Statistical Models 
Once a set of descriptors has been established for a set of experimentally verified 
compounds (active and inactive), a statistical model fits these descriptors to their observed 
behavior. It is this model that can then be applied to a virtual database of molecules to predict 
which molecules within that library are likely to be as active as or more active than those in the 
known set. The relationship between QSAR descriptor and biological activity can be modeled as 
either a linear or non-linear relationship, depending on the complexity of the system as well as 
the computational resources available. Linear models are most commonly one of three 
methods: multivariable linear regression analysis (MLR), principal component analysis (PCA), or 
partial least square analysis (PLS) [34]. MLR is generally the most time consuming method and 
involves the stepwise addition or removal of descriptors to find the set that can provide the 
most accurate predictions. This method can require a large number of training compounds as 
the general rule of thumb is that 4-5 molecules are required for every descriptor used.  PCA 
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increases the efficiency of MLR by extracting information from multiple variables into a smaller 
number of uncorrelated variables but results are not always straightforward [77, 78]. PCA can be 
used with a much smaller set of compounds than MLR. PLS combines MLR and PCA and extracts 
the dependent variable (biological activity) into new components to optimize correlations [79]. 
PCA or PLS are commonly used for model development with CoMFA [34].  
Machine Learning 
Neural networks are the most popular non-linear regression models applied to QSAR-
based drug discovery [80]. These models are based on a self-learning algorithm where the 
neural network learns the relationship between descriptors and biological activity through 
iterative prediction and improvement cycles [34]. A major drawback of neural networks is the 
fact that they are sensitive to overtraining resulting in excellent performance within the training 
set but reduced ability to assess novel compounds.  
Another machine learning method, the Support Vector Machine (SVM), separates 
compounds into groups of actives and inactives. It does this by projecting the descriptors of the 
training compounds onto a multidimensional feature space where a single “hyperplane” is 
capable of separating the two groups [81]. SVMs have also been applied to separate proteins 
into druggable and non-druggable classes. The descriptors generated for proteins can be 
performed with commercial tools such as PROFEAT and ProtParam and include features such as 
amino acid composition, secondary structure, solvent accessibility and surface properties, as 
well as descriptors seen with compound analysis such as hydrophobicity, polarity, polarizability, 
and charge. 
QSAR Application in LB-CADD 
QSAR has been used to screen for novel therapeutics in the same way both 
pharmacophore models and fingerprint similarity methods have been applied to virtual libraries. 
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Casanola-Martin et al used Dragon software to define descriptors for tyrosinase inhibitors. 
These descriptors include constitutional, topological, BCUT, Galvez, topological charge, 2D 
autocorrelations, empirical properties and descriptors, and created a model using linear 
discriminant analysis. In vitro testing revealed their most potent inhibitor with an IC50 of 1.72 
µM. This presents a more potent inhibition of tyrosinase than the current reference drug L-
mimosine (IC50 = 3.68 μM) [82]. 
Mueller et al used QSAR and artificial neural networks to identify novel positive and 
negative allosteric modulators of mGlu5. This receptor has been implicated in neurological 
disorders including anxiety, Parkinson’s disease, and schizophrenia [83, 84]. For the 
identification of positive allosteric modulators (PAMs), they first performed a traditional high 
throughput screen of approximately 144,000 compounds. This screen yielded a total of 1,356 
hits, a hit rate of 0.94%. The dataset from this HTS was then used to develop a QSAR model that 
could be applied to a virtual screen. To generate the QSAR model, a set of 1,252 different 
descriptors across 35 categories were calculated using the ADRIANA software package. The 
descriptors included scalar, 2-dimensional, and 3-dimensional descriptor categories. A statistical 
model was created with an artificial neural network and the authors iteratively removed the 
least sensitive descriptors through several rounds in order to create the optimal set. This final 
set included 276 different descriptors, including scalar descriptors such as molecular weight up 
to 3D descriptors including the radial distribution function weighted by lone-pair 
electronegativity and pi electronegativity. A virtual screen was performed against approximately 
450,000 commercially available compounds in the ChemBridge database. 824 compounds were 
tested experimentally for the potentiation of mGlu5 signaling. Of these compounds, 232 were 
confirmed as potentiators or partial agonists. This hit rate of 28.2% was approximately thirty 
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times greater than that of the traditional HTS and the virtual screen took approximately one 
hour to complete once the model had been optimized[85]. 
In a separate study, Mueller et al [86] used a similar approach to identify negative 
allosteric modulators for mGlu5. Rodriguez et al had previously performed a traditional HTS 
screen of 160,000 compounds for allosteric modulators of mGlu5 and found 624 antagonists 
[87]. QSAR and artificial neural networks were used to generate predictive models trained on 
the dataset from Rodriguez et al that were then used to virtually screen for novel negative 
allosteric modulators of mGlu5. The software package ADRIANA was used to generate all 
descriptors from 35 different categories and iterative rounds of optimization through input 
sensitivity analysis were performed resulting in a final set of 763 descriptors. The statistical 
model was used to virtually screen over 700,000 commercially available compounds in the 
ChemDiv Discovery database. Hits were filtered for drug-like properties and fingerprint 
techniques were used to remove hits that were highly similar to provide the most variable set of 
compounds. 749 compounds were tested in vitro and 27 compounds were found to modulate 
mGlu5 signaling. This hit rate of 3.6% was a significant increase over the .22% hit rate of the 
traditional HTS screen. The most potent of the compounds showed IC50’s in vitro of 75 and 124 
nM and contained a previously unidentified scaffold.  
In addition to predicting the behavior of novel compounds within a virtual library, QSAR 
has been used as a means to improve the enrichment of compound libraries that will be used in 
traditional high-throughput screening. While many chemical libraries are constructed in a 
combinatorial manner, it has been reported that combinatorially synthesized libraries do not 
cover the chemical space of known drugs and natural products and therefore first-in-class drugs 
with novel scaffolds will be difficult to find using combinatorial synthesis and high-throughput-
screening [88]. Additionally, the number of chemical structures with molecular weight under 
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500 Daltons has been estimated to be 1063, making it necessary to devise strategies in which 
compounds can be selectively generated to cover the widest area of chemical space possible 
[89]. 
QSAR has also been applied to de novo drug design techniques when structural 
information regarding the target is unknown. Descriptor and model generation is performed and 
is used to score the de novo generated molecules in place of other structure-based scoring 
techniques such as docking. Most commonly, these involve evolutionary algorithms where 
evolved structures are repeatedly modified and their biological activities are estimated using 
QSAR models. Modifications are achieved by randomly changing a part of the structure. Ligand-
based de novo drug design, however, is less practiced than structure-based de novo design due 
to the inherent challenges in the absence of receptor structure such as difficulty in extracting 
relevant information from the ligands alone, ensuring that the generated structures are diverse 
given an often limited supply of reference structures, and ensuring that generated structures 
are useful in drug discovery. In addition to QSAR methods for scoring generated molecules, 
simulated receptors and similarity based methods have been applied [90-95]. Feher et al used 5 
selective norepinephrine reuptake inhibitors as a training set to generate 2200 molecules using 
a combination of structural similarity, 2D pharmacophore similarity, and properties to drive the 
evolution[96]. One of the top scoring compounds was found to be highly active and has been 
selected as a lead compound in a project at Neurocrine[96].  
Golla, et al. applied QSAR-based methods to the design of novel chemical penetration 
enhancers (CPEs) to be used in transdermal drug delivery [97]. This group used a genetic 
algorithm to design novel CPE’s. In this paradigm, new molecules are generated based on 
crossover and mutation operations randomly applied to candidates. All generated molecules 
were scored based on the QSAR model and predicted property values and the highest scoring 
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molecules were retained for new rounds of evolution. 272 CPE’s were used both to generate the 
QSAR model as well as provide seed molecules for the genetic algorithm. The QSAR model was 
created using sequential regression analysis and heuristic analysis using CODESSA and contained 
a final set of 40 descriptors that optimally predicted properties including skin penetration 
coefficient, logP, melting point, skin sensitization, and irritation.  
The top scoring molecules were validated experimentally for permeation and toxicity 
using Franz Cell with porcine skin and HPLC analysis as well as toxicity effects on human foreskin 
fibroblasts and porcine abdominal skin. The study resulted in the identification of 18 novel 
CPE’s, 4 of which showed minimal or no toxic effects [97].  
Hoeglund used QSAR modeling combined with synthetic optimization in a follow-up to 
their most potent hit from a 2008 in silico screen for inhibitors of autotaxin. Autotaxin is an 
autocrine motility factor and has been linked to cancer progression, multiple sclerosis, obesity, 
diabetes, Alzheimer’s Disease , and chronic pain through the production of LPA [98-103]. 
Analogues of the lead compound were tested and four of the 30 exhibited IC50 less than or equal 
to the lead. The most potent compound showed 3-fold higher affinity for autotaxin than the 
lead while another compound showed 2-fold higher affinity [104]. 
Over the past several decades, over 18,000 QSAR models have been reported for a 
variety of targets with a variety of descriptors. Hansch et al have carefully collected these into a 
comprehensive database of QSAR models called C-QSAR [105]. This collection has provided not 
only access to models for novel applications, but allows the analysis of QSAR models to find 
areas of problems and improvement demands. Kim et al examined the C-QSAR database for 
outlier patterns (compounds that showed poor prediction when the average prediction for the 
model was good) and found that over the 47 QSAR models examined, the number of 
compounds scoring as outliers ranged from 3% to 36% and 26 of the 47 datasets showed 20% or 
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more compound outliers [106]. They presented several theories as to why QSAR models are so 
sensitive to the generation of outliers. One possibility came from analysis of the RCSB protein 
databank where they discovered examples where related analogs were shown to bind in very 
different poses. Another explanation presented was the confounding variable inherent in many 
QSAR-based methods, that of protein flexibility. Protein flexibility may allow odd-shaped 
compounds to bind and exert an effect by conforming to the structural inconsistencies, 
presenting difficulty in relating the characteristics of an unusual ligand with those of the more 
common ligands in the training set [106]. 
 
Conclusions 
 CADD is a useful and important tool in the discovery of novel therapeutics. It can be 
used to reduce the number of compounds necessary to screen in the search for a novel lead 
thereby reducing the costs and workload associated with a full-scale HTS endeavor.  Virtual HTS 
projects can be performed using computational tools that are capable of screening many more 
compounds than traditional HTS at a reduced cost. These tools use sophisticated algorithms to 
predict activity against a target of interest and prioritize future in vitro and in vivo experiments.  
Over the past twenty years, CADD has proven to be a viable method in the discovery of novel 
leads and therapeutics.  
 Ligand-based CADD describes a branch of CADD that uses sets of known active and 
inactive compounds against a target of interest to predict activities for novel compounds and 
screen virtual compound libraries. These methods are preferable when information of the target 
structure is unknown. Several types of ligand-based CADD, ranging in complexity have been 
applied to drug discovery. The most naïve of these approaches is molecular fingerprints that aim 
to describe the presence or absence of specific functional groups. Pharmacophore overlaying 
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involves the superimposition of known active compounds to map the distribution of chemical 
features that are common amongst all of the actives. vHTS using pharmacophores searches for 
compounds containing the same distribution of features  as those common to the known 
actives. QSAR applies a wide range of descriptors that can be scalar, 2D, or 3D in nature to 
numerically represent the information contained within a molecular structure most important 
for its biochemical behavior. Statistical or machine learning techniques are applied to construct 
models that can quantitatively predict behavior of compounds from their numerical 
representations.  
 These methods have been applied extensively to vHTS projects, resulting in the 
discovery of novel, highly potent compounds. Additionally, they have been used to improve the 
properties of previously identified lead compounds, and aid in hit list prioritization through 
similarity and clustering analysis. However, LB-CADD continues to see improvements by way of 
more sophisticated alignment and scoring algorithms, more informative descriptors, and 
improved model generation. In the following chapter, I present a novel QSAR descriptor that 
addresses some shortcomings regarding enantioselectivity with traditional 3D-QSAR in an effort 
to produce models with increased predictability and improved performance in vHTS. 
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CHAPTER II 
 
BCL::EMAS – Enantioselective Molecular Asymmetry Descriptor for 3D-QSAR 
 
Introduction 
Stereoisomers are defined as different molecular species of equal constitution which are 
separated by energy barriers[107]. For organic molecules, stereochemistry is most frequently 
caused by carbon atoms with four different substituents. However, other stereo-centers exist 
such as positively charged nitrogen atoms with four different substituents, double bonds with 
different substituents on each of the two carbon atoms, stereoisomeric allenes, atropisomeric 
biphenyls, etc. Enantiomers are a subset of stereoisomers that are defined as non-
superimposable mirror images (enantios being Greek for opposite and meros for part). Despite 
their structural similarities, enantiomers can display very different pharmacological profiles. 
Stereoisomers that are not enantiomers are called diastereomers. Stereoselectivity is widely 
prevalent in nature as most proteins are formed from the genetically encoded L-amino acids 
making small molecule binding pockets enantio-selective[108]. In drug discovery, there are 
examples in which different enantiomers show different efficacies, e.g. dexrabeprazole[109] and 
beta blockers[110], and different toxicities, e.g. levobupivacaine[111]. In 1992, the FDA issued a 
statement requiring that the development of any racemate (mixture of a compound’s 
stereoisomers) carries a justification for the inclusion of both isomers[112] and in the year 2000, 
chiral drugs accounted for over $100 billion in sales[113]. Between 1985 and 2004, the number 
of single enantiomer drugs as a percentage of chiral molecules increased from 31.6% to 
89.8%[114]. 
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Given the importance of stereoselectivity in drug design, it is necessary that any 
computational approach to drug discovery distinguishes between stereoisomers. In Structure-
Based Computer-Aided Drug Discovery (SB-CADD) stereochemistry is explicitly accounted for as 
the molecule is docked into a structural model of the protein binding site. The 3D structure of 
the molecule in complex with the protein is evaluated taking its stereochemistry into account. In 
complex with the target protein even enantiomers turn into diastereomers and can be 
distinguished. In Ligand-Based Computer-Aided Drug Discovery (LB-CADD) the chemical 
structure of active compounds is compared to derive common features that determine activity. 
The task of distinguishing stereoisomers and in particular enantiomers becomes more 
challenging as stereochemistry needs to be defined in the absence of the protein. This is 
impossible in 2D molecular descriptors where only the constitution of a molecule is taken into 
account. Therefore, extensions to 2D molecular descriptors have been developed – sometimes 
described as 2.5D descriptors – that describe configuration and can therefore define 
stereochemistry. Lastly, 3D descriptors based on the molecular conformation can define 
stereochemistry, if appropriately designed. 
The IUPAC convention for distinguishing stereoisomers is the Cahn-Ingold-Prelog (CIP) 
convention distinguishing R (rectus) and S (sinister) configuration of stereocenters. It requires a 
priority weighting system for the different substituents that is incapable of dealing with some 
complex scenarios. Extensions to the CIP system have been introduced to handle situations in 
which the chiral center did not rest on an atom but rather a chirality plane or axis and for 
stereoisomers which do not possess centers of chirality at all (stereisomeric allenes, 
atropisomeric biphenyls, and ansa-compounds)[107]. Further complications arise for 
pseudoasymmetric stereogenic units, defined as pairs of enantiomorphic ligands together with 
two ligands which are non-enantiomorphic. In cases such as these, the priorities of two 
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substituents depend on their own chiral centers. One particular disadvantage is that the CIP 
nomenclature does not always follow chemical intuition. For example, take the two molecules 
HC(CH3)(OH)F and HC(CH3)(SH)F. Naively we would align these close derivatives by 
superimposing H with H, CH3 with CH3, OH with SH and F with F. This assigns R-HC(CH3)(OH)F to 
S-HC(CH3)(SH)F and vice versa. In result, closely related derivatives that place similar functional 
groups in the same regions of space and are likely to have similar activity can have opposite CIP 
assignment. Therefore, the CIP convention is not suitable to describe stereochemistry effectively 
for LB-CADD.  
Extensions to 2D-QSAR have been proposed to distinguish enantiomers. Golbraikh and 
co-workers introduced a series of chirality descriptors that use an additional term called the 
chirality correction added to the vertex degrees of asymmetric atoms in a molecular graph 
[115]. This method is similar to one proposed by Yang and Zhong[116] where the chiral index 
was instead appended to the substituents attached to the chiral center. Multiple similar 
algorithms have also been proposed [117-120]. For example, Brown, et al[117] added chirality 
to their graph kernel method. The drawbacks of these methods include their reliance on the 
problematic R/S designations as well as the combination of spatial and atom property 
information such that their indices become a principally mathematical concept with little 
interpretation on physical terms. 
Another approach proposed by Benigni and co-workers [121] describes a chirality 
measure based on the comparison of the 3D structure for a molecule with all others in a data 
set. Zabrodsky[122] proposed a similar continuous symmetry measure which quantifies the 
minimal distance movement for points of an object in order to transform it into a shape of 
desired symmetry. However, these molecular similarity indices are very sensitive to relative 
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orientation and depend on pairwise molecular indices which can complicate QSAR-based high 
throughput screening. 
Aires-de-Sousa, et al [123-125] introduced a 3D-QSAR method for handling 
enantiomers. Classical 3D-QSAR descriptors such as radial distribution functions are incapable of 
distinguishing between enantiomers based on their nature. This method employs an RDF-like 
function that utilizes a ranking system for each chiral center introduced by Zhang and Aires-de-
Sousa that reinterpreted the CIP rules in terms of more meaningful physicochemical properties. 
Additionally, it had the benefit of being a vector rather than single value which was equal and 
opposite for enantiomer pairs. However, this method requires the identification and 
appropriate labeling of all stereogenic units and suffers from the fact that spatial information is 
combined with atom properties where some physical interpretability is lost. It is also worth 
mentioning that it is not clear if it is pharmacologically relevant to specify every stereogenic 
component of a molecule, but rather if different profiles between enantiomers depend on 
specific chiral centers and/or an overall chirality of the molecule as a whole. 
CoMFA[72] is an appealing method for distinguishing between enantiomers as it avoids 
the necessity to identify stereogenic centers. Rather, it intrinsically takes chirality into account 
as the molecular fields of chiral isomers are inherently different. However, the method relies on 
superimposition of all molecules[115] which is difficult to achieve for large or diverse substance 
libraries. 
Here we propose a novel enantio-selective 3D descriptor for QSAR that is similar to the 
RDF-like function proposed by Aires-de-Sousa and co-workers but with important differences to 
address the concerns raised above. We call this new method EMAS (Enantio-selective Molecular 
ASymmetry). Our method does not rely on any priority ranking or distinction of every 
stereogenic unit, thereby eliminating the need to combine spatial and atomic properties and 
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bypassing the difficulties that arise in non-conventional chiral centers. Rather, the enantiomeric 
distinctions “emerge” from the spatial distribution of atoms within the molecule. Additionally, 
EMAS is designed to avoid a rigid distinction between enantiomers but rather to represent the 
overall asymmetry of a molecule as it compares to other similar molecules as well as its own 
enantiomorphs. Therefore, EMAS intends to describe overall molecular asymmetry while 
including a directionality component that can distinguish between enantiomers. 
 
Results and Discussion 
 
Shape and Property Enantiomorphism 
Enantiomorphism in small molecules is impacted by two phenomena. The first factor is 
the shape of the molecule – i.e. the distributions of its atom coordinates in space. If the mirror 
image of this shape cannot be superimposed with the original version, the two molecules are 
enantiomers. Beyond the overall shape the distribution of properties plays a role. We can 
envision molecules that have a (near) perfect symmetric shape. Image and mirror image will be 
identical shape wise. However, distribution of partial charge, polarizability, and electronegativity 
can be enantiomorph. While both contributions are coupled they represent two dimensions of 
one phenomenon. For a specific molecule one of the other factors might be more pronounced. 
For example steroids can have enantiomorph shapes but have relatively uniform property 
distributions as they are dominated by apolar CH groups. On the other hand, the molecule 
CFClBrI is an almost perfect regular tetrahedron with a highly enantiomorph distribution of 
partial charge and polarizability. As both contributions can determine properties and activities 
of small molecules, stereochemical descriptors should capture and ideally distinguish both 
contributions. 
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Radial Distribution Functions separate shape information and property distribution 
Radial Distribution Functions (RDFs) are often applied in 3D-QSAR[66, 126]. As a means 
of comparison, the general form of the atomic radial distribution function is shown: 
 ( )  ∑∑     
  (     )
 
   
 
 
 
  
In this equation,   is a smoothing parameter, often called the ‘temperature’ while     is 
the distance between atoms   and  ,   is the total number of atoms in the molecule, and   is the 
running variable for the function  ( ). Often, such equations are ‘weighted’ with a property 
coefficient for both atoms     . The function plots shape (i.e. distance between two atoms) on 
the x-axis and the respective property coefficient on the y-axis thereby separating geometry 
from property distribution. With        this function is a representation of the overall shape 
of the molecule based on the frequencies of all atom pair distances within each radial distance 
step. As distances are invariant to mirroring, enantiomers share identical RDF functions. Note 
that diastereomers have distinct RDFs as not all atom pair distances are identical.  
 
Expanding RDFs to ‘signed’ volumes that are sensitive to shape enantiomorphy 
We first look for the simplest geometric form that would be sensitive to mirroring. This 
shape would be a tetrahedron. We choose tetrahedrons consisting of all combinations of three 
atoms       and the center of the molecule. Other approaches use all permutations of four 
atoms. The present approach reduces the computational demand. The geometric property 
plotted for the tetrahedron is volume.   ,   , and     are the coordinates of the three atoms. The 
center of the molecule is defined by point  . Therefore, the signed volume is computed as: 
              
 
 
(    ⃗⃗ ⃗⃗ ⃗⃗      ⃗⃗ ⃗⃗ ⃗⃗  ⃗)     ⃗⃗ ⃗⃗  ⃗ ( 
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While the absolute term always reflects volume it is important to note that the result 
can have a positive or negative sign, depending on the order of points which is initially arbitrary. 
We note that the volume has an arbitrary sign that inverts when the molecule is converted into 
its mirror image. We note further that the volume becomes 0 if the plane defined by   ,   , and 
   includes  . This property is beneficial as a planar arrangement of atoms cannot be 
enantiomorph. 
However, for a tetrahedron to contribute to enantiomorphy, its edges ‖    ⃗⃗ ⃗⃗ ⃗⃗ ‖, ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖, 
and ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖ must be of different length. This property is captured by a stereochemistry score: 
                 
(‖    ⃗⃗ ⃗⃗ ⃗⃗ ‖  ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖)  (‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖  ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖)  (‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖  ‖    ⃗⃗ ⃗⃗ ⃗⃗ ‖)
             (‖    ⃗⃗ ⃗⃗ ⃗⃗ ‖ ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖ ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖)
  ( 
Two things emerge from the numerator. The asymmetry is evaluated based on the 
variation in distances between the three atoms. If any two distances are equal, the triangle 
formed from the three atom coordinates will contain perfect symmetry and the score will be 0. 
Additionally, the directional (enantiomorphic) information emerges based on the order of 
distances. For example, if ‖    ⃗⃗ ⃗⃗ ⃗⃗ ‖ > ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖ > ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖, then this product will have a negative sign 
( )  ( )  ( ). However, if, from the vantage point of the molecular center, the order of 
distances has been shuffled (as would be seen in an enantiomer ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖ > ‖    ⃗⃗ ⃗⃗ ⃗⃗ ‖ > ‖    ⃗⃗ ⃗⃗ ⃗⃗  ⃗‖), the 
sign changes as well ( )  ( )  ( ).  Recall that by allowing a signed volume, we ensure that 
the order of distances does not rely on the order of atoms coordinates encountered, but rather 
as the order of distances seen from the molecular center in terms of the cross-product’s 
direction. 
The final directional asymmetry score (DAS) of any given atom triplet becomes: 
    √                                   
 
 ( 
35 
 
 
 
Figure 1. Calculating DAS (a) Scores reflect opposing enantiomorphs based on cross-product 
direction and geometric center. Enantiomers ((2R,3R)-2-(chloromethyl)-3-propyloxirane and 
(2S,3S)-2-(chloromethyl)-3-propyloxirane) with two stereocenters are shown. (b) Two triangles 
are visualized in both enantiomers. These triangles encompass the same triplets of atoms 
between the two molecules. Four tetramers formed by the atom triplets and molecular center 
are visualized. i, j, k, and i’, j’, k’ reflect the order of these atoms in either molecule. Importance 
of atom ordering is shown based on the direction of cross-product (red arrow) and location of 
geometric center (black circle). (c) Volume and score calculations for four tetrahedrals across 
both enantiomers are shown. Note the opposite signs and scores between the two enantiomers’ 
tetrahedrals. 
 
 
36 
 
 
Figure 2. Atom triplets in Diazepam (a) Top 5 scoring atom triplets in diazepam are shown. The 
black spot in all figures represent the geometric center of the molecule. (b) Lowest 5 scoring 
atom triplets in diazepam. All triplets shown here score 0 and do not contribute to the RDF-like 
code. (c) Top 5 positive and top 5 negative scoring triplets in diazepam. Here is visualized the 
different distribution of high scoring positive (yellow) versus high scoring negative (orange) 
triplets in diazepam. 
 
Note that for the final DAS, the product’s cube-root has been taken to achieve a 
dimension of distance resembling a common RDF. This procedure preserves the sign and 
expands the range of frequently occurring low-scoring triplets at the cost of rare triplets with 
high scores. Substituting this directional asymmetry in place of atom distance, the EMAS 
function becomes: 
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Where   is the smoothing parameter,   is the total number of non-hydrogen atoms, 
and   is the running variable of the function     ( ). The alternate sign preceding the 
exponential function transfers the “directionality” of the score to the overall function so that at 
any given score, the intensity reflects the subtraction of negative (one direction) from positive 
(opposite direction). Figure 3 maps the EMAS plot for epothilone B and its mirror image. 
 
Figure 3. EMAS curves for Epothilone B (a) Plotted EMAS curves for Epothilone B (blue) 
compared with its mirror image (red). X-axis represents the Directional Asymmetry Score in 
angstroms while the y-axis indicates the frequency of these scores across the entire molecule. 
(b) Atom triplets with a directional asymmetry score of approximately 0.3 angstroms. Note that 
these triangles generally cover the center of the molecule and are fairly symmetric. (c) Atom 
triplets with a directional asymmetry score of approximately 1.3 angstroms. Note that these 
triangles are further from the center of the molecule and have an asymmetric shape.  (d) Atom 
triplets with a directional asymmetry score of approximately 1.7 angstroms. Note that these 
atom triplets lie furthest from the center of the molecule and are very asymmetric. 
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As with the basic radial distribution function, the absence of any weighting coefficient 
results in a descriptor that encodes only spatial information. While this is important information 
in and of itself, the addition of a property weighting coefficient increases the utility of this 
descriptor. Since we are iterating over all atom triplets, the possibility that one atom property 
can throw off two other atom properties in unintended ways made it problematic in some cases 
to simply multiply the three atom properties together. Adding the properties, on the other 
hand, can circumvent this issue but two atom properties of equal magnitude and opposite signs 
can cancel each other out. Therefore, we retained the functionality for both property coefficient 
methods and suggest that any use of this descriptor in larger datasets test either method since 
one may outperform the other depending on the dataset. 
The single biggest drawback to our method is that it is highly sensitive to molecular 
flexibility. However, this is a common drawback seen with many 3D-QSAR techniques. By 
limiting an algorithm to a single static conformation, compounds that interact with binding sites 
while in a conformation that is different than the one used can be missed. One possible solution 
to this issue is through the use of conformational ensembles. In this case, compounds can be 
represented by a range of conformations rather than a single static conformation. Strategies 
incorporating conformational ensembles are currently being pursued in our laboratory and are 
hypothesized to increase the predictability of this descriptor, especially in molecules with a high 
degree of flexibility.  
 
Evaluation of EMAS as a Novel Descriptor 
Predictability Benchmarking: Cramer’s Steroids 
A commonly used dataset for evaluating the predictive capability of novel 
stereochemistry-based descriptors was introduced by Cramer et al. in 1988 [127] and several 
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structures were corrected in a subsequent publication [128]. These thirty-one steroid structures 
are accompanied with their experimental binding affinities to human corticosteroid-binding 
globulins (CGB) and provide a small dataset containing many stereocenters. Additionally, the 
rigidity of these compounds makes them an ideal benchmark set for 3D-QSAR algorithms 
eliminating the factor of conformational flexibility. Since EMAS can be employed in three forms: 
spatial only, property weighting coefficient via summation, and property weighting coefficient 
via multiplication, we trained three separate artificial neural network (ANN) models using 
descriptors derived in each of these three methods. To predict binding affinities over the entire 
dataset, we used a cross-validated leave-one-out approach. To compare the predictive power of 
our model versus other descriptors that have been tested against the steroid set, we calculated 
the correlation coefficient    of predicted versus actual affinities and the “cross-validated   ” 
  .  
As expected, the ANN model generated using no property weighting (solely spatial 
information) performed the worst of the three, producing a    of 0.78 and a    of 0.60. By 
weighting with a multiplicative property coefficient, the performance increased considerably, 
resulting in a    of 0.86 and a    of 0.74. Weighting with the property summation coefficient, 
yielded the best predictions with a    of 0.89 and a    of 0.78.  
Since we began with an interest in generating a molecular asymmetry descriptor that 
could distinguish between enantiomers, we wanted to ensure that the inclusion of directionality 
increased the information contained in the descriptor. Therefore, we created a version of the 
descriptor that incorporates just the absolute value of all stereochemistry scores, thereby 
eliminating all directional information while retaining all other spatial information. We found 
that by training our model without directional information, the predictive capabilities for the 
steroid affinities decreased to a    of 0.65 and a    of 0.41, reinforcing our original design to 
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capture stereochemistry. We also compared the model employing EMAS with one created with 
a traditional RDF. This model performed worse than any of our three methods giving a    of 
0.75 and a    of 0.56. Weighting the RDF’s with the same properties used to weight EMAS did 
not produce any significant improvement in the model (data not shown). Cross-validated 
predictions for all variations of EMAS as well as the experimental affinities can be found in Table 
1. 
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Table 1. Experimental and predicted binding affinities for the 31 Cramer’s steroids using 
novel stereoselective descriptor to train ANN models. Spatial predictions utilize the novel 
descriptor without any atom property weighting. Multiply properties utilize the novel descriptor 
weighted by the product of atom properties. Sum properties utilize the novel descriptor 
weighted by the sum of atom properties. 
 
 
Molecule 
Observed 
CBG 
affinity 
(pKa) 
Predicted 
[spatial] 
Predicted 
[multiply 
properties] 
Predicted 
[sum 
properties] 
Predicted 
[no stereo-
chemistry] 
aldosterone -6.28 -7.47 -7.31 -7.25 -7.22 
androstanediol -5.00 -5.47 -5.46 -5.33 -5.56 
5-androstenediol -5.00 -5.47 -5.43 -5.36 -5.75 
4-androstenedione -5.76 -5.64 -5.60 -5.79 -6.36 
androsterone -5.61 -5.78 -5.81 -5.55 -5.42 
corticosterone -7.88 -7.30 -7.37 -7.32 -7.34 
cortisol -7.88 -7.63 -7.58 -7.64 -7.33 
cortisone -6.89 -7.22 -6.83 -7.39 -7.07 
dehydroepiandrosterone -5.00 -5.39 -5.13 -5.46 -5.80 
11-deoxycorticosterone -7.65 -7.48 -7.47 -7.50 -6.85 
11-deoxycortisol -7.88 -7.66 -7.53 -7.59 -7.52 
dihydrotestosterone -5.92 -5.38 -5.70 -5.43 -5.96 
estradiol -5.00 -5.40 -5.36 -5.32 -5.21 
Estriol -5.00 -5.25 -5.26 -5.43 -6.10 
estrone -5.00 -5.30 -5.21 -5.54 -5.42 
etiocholanolone -5.23 -6.42 -6.44 -6.22 -6.27 
pregnenolone -5.23 -5.30 -5.25 -5.37 -6.37 
17a-hydroxypregnenolone -5.00 -5.20 -5.28 -5.29 -6.65 
progesterone -7.38 -7.17 -7.27 -7.13 -6.46 
17a-hydroxyprogesterone -7.74 -7.42 -7.39 -6.97 -6.70 
testosterone -6.72 -6.08 -6.36 -6.19 -5.94 
prednisolone -7.51 -7.61 -7.36 -7.65 -7.03 
cortisolacetat -7.55 -6.74 -6.90 -7.63 -6.00 
4-pregnene-3,11,20-trione -6.78 -6.40 -6.83 -6.09 -6.46 
epicorticosterone -7.20 -5.98 -6.00 -7.03 -7.15 
19-nortestosterone -6.14 -5.58 -5.86 -5.54 -5.45 
16a,17a-
dihydroxyprogesterone 
-6.25 -7.25 -7.04 -7.46 -7.36 
16a-methylprogesterone -7.12 -6.69 -6.39 -6.78 -6.60 
19-norprogesterone -6.82 -6.01 -6.30 -7.25 -6.19 
2a-methylcortisol -7.69 -6.62 -7.22 -7.68 -6.57 
2a-methyl-9a-fluoro-
cortisol 
-5.80 -7.56 -6.97 -6.22 -6.74 
    0.78 0.86 0.89 0.65 
    0.60 0.74 0.78 0.42 
42 
 
Since this dataset is well-established across similar descriptors in the literature, we 
compared our predictive power to other methods and found that our best    fell at the average 
   of all of these methods (0.63 <    < 0.94). This result is somewhat difficult to interpret for 
several reasons: a) different statistical models are utilized, b) different degrees of cross-
validation were employed, and c) our descriptor solely describes stereochemistry and is meant 
to be complemented by other descriptors (read below). Most of the competing descriptors 
include more information on molecule size, shape, and property distribution. However, it is 
important to note that while EMAS does not require any molecular alignment or pre-annotated 
stereocenters, it is capable of performing well with a dataset that contains a great deal of 
stereochemistry. Additionally, the inclusion of directional information outperforms a similar 
implementation lacking directional information as well as the similar RDF descriptor weighted 
with or without atom properties. For a comparison of our   with other documented tests 
against Cramer’s steroids, see table 2. 
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Table 2. Comparison of novel stereoselective descriptor predictability with other published 
QSAR methods against the Cramer’s steroid set. Calculation of    can be found in the methods 
section. Statistical model generation method is indicated as well as QSAR method employed are 
indicated for each reference. 
 
QSAR Method Model Creation q2 Reference 
Purely Spatial RDF-like 
stereochemistry 
Artificial Neural Network 0.56  
Property weight  RDF-like 
stereochemistry (product) 
Artificial Neural Network 0.74  
Property weight  RDF-like 
stereochemistry (sum) 
Artificial Neural Network 0.78  
Stochastic 3D-chiral linear indices Multiple Linear Regression 0.87 [119] 
Chiral Topological Indices Stepwise Regression Analysis 0.85 [116] 
Chiral Graph Kernels Support Vector Machine 0.78 [117] 
Chirality Correction and Topological 
Descriptors 
K-nearest neighbor 0.83 [115] 
Molecular Quantum Similarity 
Measures 
Multilinear Regression 0.84 [129] 
Shape and Electrostatic Similarity 
Matrixes 
Non-linear Neural Network 0.94 [130] 
Comparative Molecular Moment 
Analysis 
Partial Least Squares (PLS) 0.83 [128] 
Comparative Molecular Similarity 
Indices Analysis 
PLS 0.67 [131] 
Comparative Molecular Field 
Analysis 
PLS 0.65 [127] 
E-state Descriptors PLS 0.62 [132] 
Molecular Electronegativity 
Distance Vector 
Genetic Algorithm PLS 0.78 [133] 
Molecular Quantum Similarity 
Measures 
Multilinear Regression and 
PLS 
0.80 [134] 
 
vHTS Utility and Enrichment Benchmarking: PUBMED AID891 
We provide the above analysis for comparison. However, realistically the steroid dataset 
is too small to provide a good benchmark for EMAS as often the number of features (24) is in 
the same order of magnitude as the number of data points (31). Therefore we tested the 
descriptor in a more virtual high-throughput screening (vHTS) endeavor. For the benchmark 
dataset, we used publicly available results of a conformational screen for inhibitors and 
substrates of cytochrome P450 2D6 (AID 891). This dataset is of moderate size (approximately 
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10,000 molecules) and contains both active (18%) and inactive (82%) compounds. We employed 
a forward-feature selection (FFS) analysis that selects optimal descriptors from RDF’s, 3D 
Autocorrelations (3DA), and 2D Autocorrelations (2DA) labeled with atom properties including 
charge, electronegativity, and effective polarizability (see Experimental Section). For a complete 
list of features tested in forward-feature selections, please see appendix table A1. ANN 3D-QSAR 
models were trained with and without inclusion of the EMAS descriptors in the list of 
descriptors for FFS to choose from. Hence the utility of the EMAS descriptor can be evaluated in 
two ways: a) are the EMAS descriptors selected by the FFS procedure? and b) does the final 
model that includes EMAS descriptors have increased predictive power? The FFS with the 
default set of initial features resulted in a best descriptor set of 9 features distributed evenly 
across RDF’s, 3D Autocorrelations (3DA), and 2D Autocorrelations (2DA). Cross-validated 
predictions from the ANN model constructed with this feature set produced an enrichment of 
3.94 and a receiver operating characteristic (ROC) curve with an area under the curve (AUC) of 
0.826.   
An identical FFS analysis was performed by combining the default set of features with 34 
EMAS features including all three variations of EMAS (spatial, property weighting via sum, and 
property weighting via product) weighted with the same list of properties used to test RDFs, 
3DAs, and 2DAs. The best set of features contained 20 total features distributed across RDF’s, 
3DA’s, 2DA’s, number of hydrogen bond donors, and several EMAS features. There were a total 
of seven EMAS features represented in the best feature set. Therefore, almost one third of the 
total features in the best feature set generated through this analysis were EMAS features. This 
set of seven features contained a spatial EMAS weighted by Van der Waals surface areas, three 
EMAS features weighted via the product method and three EMAS features weighted via the sum 
method. This substantial representation of EMAS in the best feature set suggests that EMAS 
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successfully provides useful information for the model development that may not be 
represented in any other feature in the original set. Cross-validated predictions from the ANN 
model constructed from this EMAS-inclusive feature set produced an enrichment of 4.38 and a 
ROC curve with an area under the curve of 0.837, a clear improvement over the control model. 
Positive predictive value (PPV) is a related measure of a model’s predictive capability which 
tracks predictive precision as more and more positive predictions are made. By comparing the 
average PPV precision over a range of the fraction of total predictions made (fraction positive 
predictions, FPP) of interest, it is possible to compare predictive capabilities for two models. 
Over the FPP range of .005 to .05, we find that our model trained with the EMAS features 
performed significantly better than the model trained without EMAS features (.727 PPV 
precision compared with .651). A paired t-test for the cross-validated models comparing 
precisions in this FPP range showed that this is a statistically significant improvement (p < .005) 
over the analysis completed without EMAS features. For a complete list of the best features 
determined from both forward feature analyses, please see the appendix table A2. Comparative 
ROC and PPV curves from the forward feature analyses for the control set of features and the 
control set combined with EMAS features are shown in figure 4. 
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Figure 4. ROC and PPV results for the feature forward analysis with the control set of features 
compared with the control set combined with EMAS features (a) AID891 prediction ROC curves 
generated from the ANN models trained with the best descriptor set generated from the 
forward feature analysis beginning with the control set of features combined with the novel 
EMAS features (red) show improved performance when compared with ROC curves generated 
from the ANN models trained with the best descriptor set generated from the forward feature 
analysis beginning with the control set of features (blue) (b) PPV curves for models trained with 
the best descriptor set of control features combined with the EMAS features (red) shows 
improved performance over those models trained with the best descriptor set of control 
features only (blue). Dashed lines of corresponding colors show the average PPV values over the 
FPP region from which the models were optimized (.005 to .05 fraction positive predicted 
values). 
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Conclusions 
The goal of this project was to develop a 3D-QSAR descriptor that was capable of not 
only distinguishing between enantiomers but of describing the overall degree of asymmetry for 
a molecule. This was accomplished by developing an RDF-like curve that described the 
distribution of ‘directional asymmetry scores (DAS)’ rather than inter-atomic distances. The DAS 
is designed to incorporate information regarding the degree and direction of asymmetry 
between each atom triplet in the molecule. The degree of asymmetry is calculated as a product 
of how asymmetrically the three atoms are distributed and the distance they lie from the center 
of the molecule. This asymmetry is related to the differences between their interatomic 
distances and the distance from the center of the molecule is related to the volume of the 
tetrahedron created by the three atom coordinates and the geometric center of the molecule. 
The direction of asymmetry is related to the distribution of the interatomic distances between 
these three atom coordinates from the point of view of the center of the molecule. If the sides 
of the triangle created by these three atoms are different, then identical triangles “pointing” in 
opposite directions will have a different ordering of sides depending on which direction they 
“point.” This is the key variable that allows the descriptor to distinguish between enantiomers. 
To exclude any influence that the order in which atoms are listed in the molecule may play on 
this directionality scheme, we offset this by incorporating the cross-product of the two vectors 
created from the three atoms. This cross-product will swap signs were the atoms are ordered 
differently thereby eliminating the influence of the order of atoms. 
We tested the value of this descriptor by training ANN 3D-QSAR models. In order to 
provide a basis of comparison with other documented QSAR methods that address 
stereoselectivity, we used a small dataset of steroids that is commonly used as a benchmark for 
these types of descriptors. We found that the predictability of our descriptor performed 
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comparably with other stereochemistry-based descriptors when evaluated with this set of 31 
steroids (   = 0.89,    = 0.78). Additionally, we assessed the utility of the EMAS descriptor by 
running vHTS experiment on a publically available dataset (PUBCHEM AID 891). A forward-
feature selection analysis that determines the most effective set of descriptors for this dataset 
was employed and the best set of features included several EMAS functions (7 EMAS of 20 total 
features). This set of features improved the performance of our models over those that were 
tested without EMAS functions (enrichment of 4.38 when including EMAS versus enrichment of 
3.94 without EMAS).  
We conclude that the EMAS descriptor encodes stereochemistry thereby providing 
important information that is not captured in other 3D-QSAR descriptors. There are several 
published QSAR methods that performed better than EMAS for the steroid dataset but these 
methods often require some heuristic for describing the stereocenters within each of the 
molecules or aligning the 3D structures of these molecules. By avoiding the necessity to assign a 
directional designation to each stereocenter, EMAS is capable of evaluating molecules without 
the problematic R/S annotation method. Other methods that avoid these annotations present 
their own limitations, as an additional alignment step and framework similarity is required. 
These issues limit the range of descriptor applicability and introduce more degrees of freedom. 
While our descriptor is outperformed by multiple techniques with the steroid dataset, we 
contend that this is not a very accurate comparison. The cross-validation methods used by many 
of the other methods vary and are often more forgiving than ours. Some drawbacks that EMAS 
addresses are not encountered with the steroid dataset as it is composed of very similar 
molecules with relatively simple, fully annotated stereocenters. Additionally, EMAS achieves a 
more global representation of stereochemistry that retains a physical basis and is applicable to 
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any set of molecules. This broad applicability is not found with other stereochemistry-based 
descriptors. 
In summary, EMAS provides a widely applicable stereo-sensitive descriptor that 
intrinsically incorporates physical chirality rather than describing it with abstract annotations. 
 
Methods 
 
Generation of Numerical Descriptors for QSAR Model Creation 
3D models of all small molecules were generated using the CORINA software package 
unless already defined. For feature selection analysis, a set of 2,100 numerical descriptors was 
generated using the BioChemical Library (BCL) software created in our lab. The descriptors can 
be classified into 5 categories, including six scalar descriptors (molecular weight, number of 
hydrogen bond donors, number of hydrogen bond acceptors, logP, total charge, and topological 
surface area), 18 2-dimensional auto-correlation functions, 18 3-dimensional autocorrelation 
functions, 18 radial distribution functions, and 34 novel EMAS descriptors. These 34 descriptors 
included spatially-based asymmetry functions with and without Van der Waals (VDW) surface 
area scaling, 16 property-weighted asymmetry functions based on the multiplicative scheme, 
and 16 property-weighted asymmetry functions based on the additive scheme. These properties 
included sigma charge [135-137], pi charge [138-140], Vcharge [141], total charge [135-140], 
sigma electronegativity [135-137], pi electronegativity [138-140], effective polarizability [142-
144], and lone pair electronegativity [138-140] with and without VDW surface area scaling. The 
control comparison forward feature selection analysis was performed with a feature set that 
included all features listed above except the novel EMAS features. This feature set contains 
1284 features. For steroid binding predictions, descriptor sets were created using only one 
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EMAS method and those including property weighting coefficients used the same properties 
listed. 
 
Training, Monitoring, and Independent Dataset Generation 
Cramer’s Steroids 
The dataset was split for ANN training into three subsets: training, monitoring, and 
independent. The monitoring dataset is necessary to prevent over-training. Because of the small 
size of the dataset, only one molecule was labeled independent. Five molecules were used as 
the monitoring dataset, 25 for training. The set of five molecules was incremented through the 
entire dataset for a total of 6 different monitoring sets. Leave-one-out cross-validation was 
performed where each molecule was used as the independent molecule while the remaining 30 
molecules were used for training and monitoring. The predictions were averaged across the 
different monitoring sets to yield the final activity predictions for the entire set of 31 molecules. 
PUBMED AID891 
AID 891 is a publically available dataset that can be found at 
http://pubchem.ncbi.nlm.nih.gov/. It contains 1623 active compounds and 7756 inactive 
compounds tested for inhibition of cytochrome P450 2D6. This dataset was split into 10 clusters, 
8 of which were used as the training dataset, 1 used for monitoring, and 1 used for 
independent. For cross-validation, the monitoring and independent datasets are iterated and 
then the resulting independent predictions are averaged to give the final list of predicted 
activities that spans the entire dataset. In order to maximize model performance, the dataset 
was balanced through oversampling. In other words, the active compounds were represented 
multiple times so that the number of active compounds roughly equals the number of inactive 
compounds. This method of balancing has been used to maximize QSAR models in other 
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datasets where the number of active compounds is significantly less than the number of inactive 
compounds[86].  
The pIC50 values of each compound within AID891 and the steroid binding data for the 
Cramer dataset were used as output for the ANN models. For the AID891 dataset, inactive 
compounds were set to a pIC50 value of 3. The root-mean-square deviation (RMSD) between 
predicted and experimental activities was used as the objective function for training the ANN. 
 
Artifical Neural Network (ANN) architecture and training 
For the AID891 dataset, the ANN was trained using a sigmoid transfer function with a 
simple weight update of η = 0.1 and α = 0.5. The hidden layer contained eight neurons. For the 
steroid dataset, the ANN was trained using the same protocol as the AID891 dataset but the 
number of hidden neurons was reduced to 4 due to the dataset’s much smaller size of. 
 
Forward-feature selection for optimal descriptor set selection 
Descriptor selection was performed to test the novel descriptor against all other 
implemented descriptors to see if it provided an increase to enrichment over any of the other 
descriptors. The approach begins with a single descriptor, trains a model with only that 
descriptor, and then continuously adds more descriptors one at a time, training a new model 
each round. At the completion of each round, the descriptor set that produced the lowest RMSD 
score was retained for the next round. All descriptors not present in the retained list of 
descriptors are then added individually to that retained list of descriptors and the descriptor set 
producing the best RMSD score is retained for the next round, and so on. At the completion of 
these iterations, the round that produced the best RMSD score overall is recalled as the top 
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descriptor set. If a descriptor appears in this list of best descriptors, then it suggests that 
significant information had been gleaned from that descriptor during the ANN training. 
 
Model Evaluation 
ANN models using the AID891 datasets were analyzed using receiver operation 
characteristic (ROC) curves to assess their predictive power. These curves plot the rate of true 
positives versus the rate of false positives as a fraction of the total number of positives. 
Therefore, a slope of 1 would reflect random guesses as each true positive would be statistically 
likely to be followed by a false positive. An increase in slope and area under the curve would 
indicate an increase in predictive power. The initial section of the ROC curve is often most 
important because it represents compounds with the highest predicted activity. Therefore, 
enrichment values are determined based on the slope of the ROC curve comprising the first 
subset of molecules. Increases in enrichment is often the most important measure for 
application of virtual screening in drug discovery as it reflects the expected factor at which the 
fraction of actives will be increased over an unbiased dataset. 
Positive predictive value (PPV) is a measure related to enrichment which tracks the 
model’s predictive precision as the fraction of predicted positives (FPP) increases from highest 
predicted activity to lowest. A model is likely to lose precision as the predicted activities 
approach the cutoff point and therefore it is common to specify a range of FPP of interest when 
measuring a PPV. FPP is calculated as the number of true positive predictions plus the number 
of false positive predictions divided by the size of the dataset. PPV is calculated as the number 
of true positive predictions divided by the total number of positive predictions (true and false 
positive). 
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To determine the statistical significance for the average PPV improvement over the FPP 
range of .005 to .05, we compared the average PPV within this FPP range for each combination 
of training and modeling datasets that went into the cross-validated model. By aligning these 
datasets between the two models, we were able to perform a two-tailed paired t-test to show a 
significant improvement for the cross-validated model including EMAS features over the cross-
validated model without EMAS features.  
To evaluate the utility of models trained with the steroid dataset in a way which could 
be comparable with published methods, the conventional correlation coefficient    of the 
predicted activities against actual activities and cross-validated   , also known as    were 
calculated for each descriptor set. All predicted values used in these analyses were the average 
predicted activities from each of the leave-one-out models with the different monitoring 
datasets. The     is calculated from the equation 
   
        
  
 6 
Here,    is the sum of squared deviations of each biological property from their mean 
and       (predictive residual sum of squares) is the sum of the squared differences between 
the actual biological property and the cross-validated predicted property. 
 
Implementation 
The descriptor generation and ANN algorithms were implemented in the 
BioChemistryLibrary (BCL). The training method used is simple propagation, a supervised 
learning approach. The BCL is an in house developed object oriented Library written in the C++ 
programming language. 
 
 
54 
 
APPENDIX 
 
NORMALIZATION OF STEREOCHEMISTRY SCORE 
 
The stereochemistry score is normalized based on the maximum possible stereochemistry score 
which can be computed assuming         and       
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FORWARD-FEATURE SELECTION DESCRIPTORS 
 
Table A1: Complete list of features used for the forward-feature selection of descriptors. Novel 
EMAS functions were excluded for the control forward-feature selection. 
 
 
 
 Descriptor Name Description 
Scalar descriptors Weight Molecular weight of compound  
 HbondDonor Number of hydrogen bonding acceptors 
derived from the sum of nitrogen and 
oxygen atoms in the molecule 
 HBondAcceptor Number of hydrogen bonding donors 
derived from the sum of N-H and O-H 
groups in the molecule 
 TopologicalPolarSurf
aceArea 
Topological polar surface area in [Å2] of 
the molecule derived from polar 2D 
fragments 
 LogP Octanol/water Partition coefficient 
calculated by atom-additive method[145] 
 TotalCharge Sum of atomic formal charges across 
molecule 
Vector descriptors Identity  weighted by atom identities 
2D Autocorrelation                   
(11 descriptors) 
SigmaCharge weighted by σ atom charges 
PiCharge weighted by π atom charges 
3D Autocorrelation                   
(12 descriptors) 
TotalCharge weighted by sum of σ and π charges 
SigmaEN weighted by σ atom electronegativities 
Radial Distribution 
Function               (48 
descriptors) 
PiEN weighted by π atom electronegativities 
LonePairEN weighted by lone pair electronegativities 
Novel EMAS Function 
weighted by sum of 
properties                (24 
descriptors) 
EffectivePolarizability weighted by effective atom polarizabilities 
Novel EMAS Function 
weighted by product 
of properties           (24 
descriptors)          
Vcharge weighted by partial atomic charges 
accounting for alternate resonance 
forms[141] 
Every Vector descriptor available with and without van der Waals surface area weighting 
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Table A2: Top feature sets following forward-feature selection for both conditions 
Control feature selection (without EMAS) Novel feature selection (with EMAS) 
Descriptor Type Weight Descriptor Type Weight 
Radial Distribution 
Function 
AtomIdentity  
[surface area scaled] 
Radial Distribution 
Function 
AtomIdentity  
[surface area scaled] 
Radial Distribution 
Function 
Vcharge Radial Distribution 
Function 
Vcharge 
Radial Distribution 
Function 
EffectivePolarizability 
[surface area scaled] 
EMAS  
(product weight) 
AtomIdentity  
[surface area scaled] 
3D Autocorrelation SigmaCharge 2D Autocorrelation SigmaEN  
[surface area scaled] 
Radial Distribution 
Function 
LonePairEN Radial Distribution 
Function 
PiEN  
[surface area scaled] 
2D Autocorrelation SigmaEN Scalar HbondDonor 
3D Autocorrelation SigmaEN EMAS  
(product weight) 
SigmaEN  
[surface area scaled] 
3D Autocorrelation Vcharge 
 [surface area scaled] 
2D Autocorrelation EffectivePolarizability 
[surface area scaled] 
2D Autocorrelation Vcharge  
[surface area scaled] 
3D Autocorrelation Vcharge  
[surface area scaled] 
 Radial Distribution 
Function 
PiEN 
3D Autocorrelation SigmaCharge 
2D Autocorrelation EffectivePolarizability 
EMAS (sum weight) Vcharge  
[surface area scaled] 
EMAS  
(product weight) 
Vcharge 
EMAS  
(sum weight) 
TotalCharge 
Radial Distribution 
Function 
EffectivePolarizability 
EMAS  
(sum weight) 
LonePairEN 
EMAS  
(product weight) 
PiEN  
[surface area scaled] 
3D Autocorrelation PiEN  
[surface area scaled] 
Radial Distribution 
Function 
SigmaCharge 
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